Myths and facts in the use of anti-inflammatory drugs

References

• Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip OA: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005; 64: 669–81
   PubMed Web of Science ®Google Scholar
• RBN Jones, Culpepper, L, Gass, D, Grol, R, Mant, D, Silagy, C. The nature of primary medical care. London: Oxford University Press; 2003.
   Google Scholar
• Mantyselka P, Kumpusalo E, Ahonen R, Kumpusalo A, Kauhanen J, Viinamaki H, et al. Pain as a reason to visit the doctor: a study in Finnish primary health care. Pain. 2001; 89: 175–80
   PubMed Web of Science ®Google Scholar
• Prescription cost analysis England. 2006. Information Centre for Health and Social Care; 2007 [updated 2007]. Available from:, , http://www.ic.nhs.uk/webfiles/publications/pca2006/PCA_2006.pdf. (accessed 1 Jan 2006).
   Google Scholar
• Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006; 1: CD004257
   PubMed Web of Science ®Google Scholar
• Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005; 42: 1364–72
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol. 2007; 34: 543–55
   PubMed Web of Science ®Google Scholar
• Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med. 2007; 167: 1752–9
   PubMed Web of Science ®Google Scholar
• Barnard L, Lavoie D, Lajeunesse N. Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern. Drug Saf 2006; 29: 613–20
   PubMed Web of Science ®Google Scholar
• Roumie CL, Arbogast PG, Mitchel EF, Jr, Griffin MR. Prescriptions for chronic high-dosecyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. J Gen Intern Med 2005; 20: 879–83
   PubMed Web of Science ®Google Scholar
• Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008; 28: S25–32
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2003; 49: 508–18
   PubMed Web of Science ®Google Scholar
• Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002; 29: 804–12
   PubMed Web of Science ®Google Scholar
• Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000; 85: 169–82
   PubMed Web of Science ®Google Scholar
• Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev. 2005; 48: 352–9
   PubMedGoogle Scholar
• Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092–102
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071–80
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332: 1302–8
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002; 106: 1893–900
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001; 52: 563–71
   PubMed Web of Science ®Google Scholar
• Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 136: 161–72
   PubMed Web of Science ®Google Scholar
• Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding?. Am J Med. 2006; 119: 719–27
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284: 1247–55
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343: 1520–8
   PubMed Web of Science ®Google Scholar
• Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999; 282: 1929–33
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001; 96: 1019–27
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004; 364: 665–74
   PubMed Web of Science ®Google Scholar
• Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006; 131: 1674–82
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Garcia-Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000; 160: 2093–9
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ. 1997; 315: 1333–7
   PubMed Web of Science ®Google Scholar
• Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006; 55: 1731–8
   PubMed Web of Science ®Google Scholar
• Scarpignato CBI, Bretagne J-F, De Pouvourville G, García Rodríquez LA, Goldstein JL, Müller PA, et al. Working team report: towards a GI safer antiinflammatory therapy. Gastroenterology Int. 1999; 12: 186–215
   Google Scholar
• Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum. 2005; 53: 185–97
   PubMed Web of Science ®Google Scholar
• Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum. 2002; 32: 25–32
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Eisen GM, Burke TA, Pena BM, Lefkowith J, Geis GS. Dyspepsia tolerability from the patients’ perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther. 2002; 16: 819–27
   PubMed Web of Science ®Google Scholar
• Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000; 160: 2998–3003
   PubMed Web of Science ®Google Scholar
• Eisen GM, Goldstein JL, Hanna DB, Rublee DA. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment Pharmacol Ther. 2005; 21: 591–8
   PubMedGoogle Scholar
• Goldstein JL, Bello AE, Spalding W, Suh S, Fort JG. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. J Rheumatol. 2005; 32: 111–7
   PubMed Web of Science ®Google Scholar
• Pilotto A, Franceschi M, Vitale DF, Zaninelli A, Masotti G, Rengo F. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs. Aliment Pharmacol Ther. 2005; 22: 147–55
   Google Scholar
• Rahme E, Toubouti Y, Hunsche E. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rheumatology (Oxford) 2006; 45: 903–10
   Google Scholar
• Wolfe F, Michaud K, Burke TA, Zhao SZ. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol. 2004; 31: 355–8
   PubMed Web of Science ®Google Scholar
• Spiegel, BM, Farid, M, Dulai, GS, Gralnek, IM, Kanwal, F. Comparing rates of dyspepsia with Coxibs vs NSAID + PPI: a meta-analysis. Am J Med. 2006;119:448: e27–36.
   Google Scholar
• Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Langstrom G, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol. 2005; 100: 1028–36
   PubMed Web of Science ®Google Scholar
• Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2006; 24: 751–67
   PubMed Web of Science ®Google Scholar
• Lanas A, Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?. Digestion. 2006; 73(Suppl. 1)136–50
   Google Scholar
• Scarpignato C. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target?. Gut. 2008; 57: 145–8
   PubMed Web of Science ®Google Scholar
• Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med. 2006; 38: 415–28
   PubMed Web of Science ®Google Scholar
• Pozzoli C, Menozzi A, Grandi D, Solenghi E, Ossiprandi MC, Zullian C, et al. Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. Naunyn Schmiedebergs Arch Pharmacol. 2007; 374: 283–91
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, Bhadra P, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007; 25: 1211–22
   PubMed Web of Science ®Google Scholar
• Goldstein, JL, Eisen, GM, Lewis, B, Gralnek, IM, Zlotnick, S, Fort, JG; on behalf of the Investigators. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133–41.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999; 45: 362–6
   PubMed Web of Science ®Google Scholar
• Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut. 2001; 48: 339–46
   PubMed Web of Science ®Google Scholar
• Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut. 2000; 47: 527–32
   PubMed Web of Science ®Google Scholar
• Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. Clin Gastroenterol Hepatol. 2004; 2: 113–20
   PubMed Web of Science ®Google Scholar
• Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med. 2000; 109: 201–6
   PubMed Web of Science ®Google Scholar
• Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans J, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther. 2003; 17: 201–10
   PubMed Web of Science ®Google Scholar
• Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001; 19(Suppl 1)33–47
   Google Scholar
• Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003; 124: 288–92
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008; 135: 1517–25
   PubMed Web of Science ®Google Scholar
• Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med. 2004; 164: 1243–6
   PubMedGoogle Scholar
• Moore RA, Derry S, Phillips CJ, McQuay HJ. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006; 7: 79
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368: 1771–81
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007; 132: 498–506
   PubMed Web of Science ®Google Scholar
• Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006; 119: 255–66
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Agrawal NM, Silverstein FE, Verburg KM, Burr AM, Hubbard RC, et al. Influence of H. pylori (Hp) infection and/or low dose aspirin (ASA) on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDs. Gastroenterology. 1999; 116: A174
   Web of Science ®Google Scholar
• Goldstein J, Kent J, Shu V, Maurath C, Recker D, Verburg K. Valdecoxib is less ulcerogenic than conventional NSAIDs in osteoarthritis (OA) and rheumatoid arthritis (RA) patients with high risk of peptic ulcer disease. Gastroenterology. 2002; 122: A344
   Google Scholar
• Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004; 127: 395–402
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005; 7: R644–65
   PubMed Web of Science ®Google Scholar
• Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000; 321: 1183–7
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Aisenberg J, Zakko SF, Berger MF, Dodge WE. Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial. Dig Dis Sci. 2008; 53: 647–56
   Google Scholar
• Rahme E, Bardou M, Dasgupta K, Toubouti Y, Barkun A. Gastrointestinal effects of rofecoxib and celecoxib versus NSAIDs among patients on low dose aspirin. Gastroenterology 2004; 126(Suppl 2)A1–2
   Google Scholar
• Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001; 110(Suppl 3A)28S–32S
   PubMedGoogle Scholar
• MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003; 361: 573–4
   PubMed Web of Science ®Google Scholar
• Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006; 80: 264–74
   PubMed Web of Science ®Google Scholar
• Stichtenoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Des. 2000; 6: 1737–53
   PubMed Web of Science ®Google Scholar
• Stichtenoth DO, Marhauer V, Tsikas D, Gutzki FM, Frolich JC. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int. 2005; 68: 2197–207
   PubMedGoogle Scholar
• Sturmer T, Erb A, Keller F, Gunther KP, Brenner H. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med. 2001; 111: 521–7
   PubMedGoogle Scholar
• Murray MD, Brater DC, Tierney WM, Hui SL, McDonald CJ. Ibuprofen-associated renal impairment in a large general internal medicine practice. Am J Med Sci. 1990; 299: 222–9
   Google Scholar
• Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002; 347: 2104–10
   PubMed Web of Science ®Google Scholar
• Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005; 165: 490–6
   PubMed Web of Science ®Google Scholar
• Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004; 44: 140–5
   PubMed Web of Science ®Google Scholar
• Brater DC, Anderson SA, Brown-Cartwright D, Toto RD. Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics. Am J Kidney Dis. 1986; 8: 351–5
   PubMed Web of Science ®Google Scholar
• Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005; 330: 1370
   PubMed Web of Science ®Google Scholar
• Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004; 363: 1751–6
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006; 116: 4–15
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006; 5: 75–86
   PubMed Web of Science ®Google Scholar
• Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum. 2003; 48: 12–20
   PubMedGoogle Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286: 954–9
   PubMed Web of Science ®Google Scholar
• Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007; 66: 1296–304
   PubMed Web of Science ®Google Scholar
• Joshi GP, Gertler R, Fricker R. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Anesth Analg. 2007; 105: 1793–804
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005; 352: 1081–91
   PubMed Web of Science ®Google Scholar
• ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1:e33.
   PubMedGoogle Scholar
• Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004; 109: 1468–71
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005; 330: 1366
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005; 165: 978–84
   PubMed Web of Science ®Google Scholar
• Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006; 113: 1578–87
   PubMed Web of Science ®Google Scholar
• Abraham NS, El-Serag HB, Hartman C, Richardson P, Deswal A. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther. 2007; 25: 913–24
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296: 1633–44
   PubMed Web of Science ®Google Scholar
• Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther. 2006; 8: R153
   PubMed Web of Science ®Google Scholar
• Singh G, Graham D, Wang H, Mithal A, Triadafilopoulos G. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis. 2006; 65: S61
   Google Scholar
• Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet. 2007; 370: 2138–51
   PubMed Web of Science ®Google Scholar
• Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation. 2005; 111: 249
   PubMed Web of Science ®Google Scholar
• Lagakos SW. Time-to-event analyses for long-term treatments—the APPROVe trial. N Engl J Med. 2006; 355: 113–7
   PubMed Web of Science ®Google Scholar
• Leone A. Smoking, haemostatic factors, and cardiovascular risk. Curr Pharm Des. 2007; 13: 1661–7
   PubMed Web of Science ®Google Scholar
• Brophy JM, Levesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007; 93: 189–94
   PubMed Web of Science ®Google Scholar
• Loboz KK, Shenfield GM. Drug combinations and impaired renal function—the ‘triple whammy’. Br J Clin Pharmacol. 2005; 59: 239–43
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?. Am J Med. 2006; 119: 113–6
   PubMed Web of Science ®Google Scholar
• Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004; 164: 2367–70
   PubMedGoogle Scholar
• Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006; 23: 937–44
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999; 319: 1106–9
   PubMed Web of Science ®Google Scholar
• van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001; 323: 655–8
   PubMed Web of Science ®Google Scholar
• Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003; 163: 59–64
   PubMed Web of Science ®Google Scholar
• Dunn NR, Pearce GL, Shakir SA. Association between SSRIs and upper gastrointestinal bleeding. SSRIs are no more likely than other drugs to cause such bleeding. BMJ. 2000; 320: 1405–6
   Google Scholar
• Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJ, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?. Aliment Pharmacol Ther. 2005; 22: 175–81
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Montero D, Garcia-Rodriguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2006; 98: 304–10
   PubMed Web of Science ®Google Scholar
• Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy. 2006; 26: 1307–13
   PubMed Web of Science ®Google Scholar
• Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008; 27: 31–40
   PubMed Web of Science ®Google Scholar
• Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing?. CNS Drugs. 2006; 20: 143–51
   PubMed Web of Science ®Google Scholar
• Helin-Salmivaara A, Huupponen R, Virtanen A, Lammela J, Klaukka T. Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2005; 61: 425–31
   Google Scholar
• de Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 2003; 55: 591–5
   PubMedGoogle Scholar
• Helin-Salmivaara A, Huttunen T, Gronroos JM, Klaukka T, Huupponen R. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur J Clin Pharmacol. 2007; 63: 403–8
   PubMed Web of Science ®Google Scholar